WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

Summary

This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.

Timeline

Start

2022-05-05

Primary completion

2028-01

Completion

2028-06

Drugs

Indications